Daily Cardiology Research Analysis
Analyzed 166 papers and selected 3 impactful papers.
Summary
Three impactful cardiology studies stood out: a prospective multicenter validation defined safe, efficient rule-out cutoffs for a new high-sensitivity troponin I assay; a mechanistic Circulation study identified IL-8–mediated fibroblast–cardiomyocyte crosstalk driving Noonan syndrome hypertrophic cardiomyopathy and reversed pathology with reparixin; and a large real-world analysis showed PCSK9 inhibitor monoclonal antibodies reduced ischemic events and mortality in ASCVD patients without prior events.
Research Themes
- High-sensitivity cardiac troponin rule-out algorithms and assay-specific implementation
- Cytokine-mediated cardiac fibroblast–cardiomyocyte crosstalk as a therapeutic target in hypertrophic cardiomyopathy
- Real-world effectiveness of PCSK9 inhibitors in primary prevention within ASCVD populations
Selected Articles
1. Alternative Rule-Out Cutoffs for a Novel High-Sensitivity Cardiac Troponin I Assay in Patients With Suspected Myocardial Infarction.
A prospective multicenter derivation/validation study showed that using the assay’s limit of quantification (≤2 ng/L) alone (if onset >3 hours) or with a 1-hour delta ≤1 ng/L safely ruled out MI with 99.1% sensitivity, excluding about half of ED chest pain patients. Predefined rule-in thresholds provided high specificity, and findings were replicated for a 0/2-hour pathway.
Impact: This provides assay-specific, prospectively validated cutoffs aligned with regulatory LOQ that can immediately standardize and streamline ED MI pathways while maintaining safety.
Clinical Implications: Emergency departments can adopt LOQ-based 0/1- or 0/2-hour algorithms for hs-cTnI-VITROS to safely expedite rule-out decisions, reduce observation time and crowding, and harmonize protocols across sites.
Key Findings
- In 2,931 patients, MI prevalence was 16%, and LOQ ≤2 ng/L with 1-hour delta ≤1 ng/L ruled out 51% with 99.1% sensitivity.
- Direct rule-out at ≤2 ng/L was safe when symptom onset was >3 hours.
- Rule-in criteria (0 h ≥40 ng/L or 1 h delta ≥4 ng/L) identified 16.9% with 95.9% specificity; results replicated in an independent validation cohort and with a 0/2-hour algorithm.
Methodological Strengths
- Prospective, multicenter derivation and validation with blinded central adjudication
- Predefined rule-in/out thresholds with assay-specific implementation and replication across 0/1- and 0/2-hour pathways
Limitations
- Single-assay specificity limits generalizability to other platforms without dedicated validation
- Not an outcomes trial; operational impact and safety beyond diagnostic adjudication were not assessed
Future Directions: Evaluate clinical and operational outcomes (length of stay, downstream testing, patient safety) after implementation; extend validation to diverse populations and other hs-cTnI platforms.
BACKGROUND: There is major uncertainty among physicians on how to best use the novel hs-cTnI (high sensitivity-cardiac troponin I)-VITROS assay, as the limit of quantification (2 ng/L), applied by the US Food and Drug Administration and other regulators, is higher than the limit of detection (1 ng/L)-based rule-out cutoffs from recent pilot studies for 0/1-hour and 0/2-hour algorithms. METHODS: This prospective, multicenter study aimed to derive and validate higher limit of quantification-based assay-specific cutoffs for safe and efficient rule-out of myocardial infarction among adult patients presenting with acute chest discomfort to the emergency department. Final diagnoses of myocardial infarction were centrally adjudicated by 2 independent cardiologists, blinded to hs-cTnI-VITROS concentrations. RESULTS: Among 2931 eligible patients, 467 (16%) were diagnosed with myocardial infarction. In the derivation cohort (n=1466), a cutoff ≤2 ng/L at presentation in patients with chest pain onset >3 hours (direct rule-out) and ≤2 ng/L in combination with a 1-hour absolute change of ≤1 ng/L ruled out 51% of patients, with a sensitivity of 99.1% (96.9%-99.8%). Predefined rule-in thresholds (0 hour-value ≥40 ng/L [direct rule-in] or an absolute change within 1 hour of ≥4 ng/L) identified 16.9% of patients, with a specificity of 95.9% (94.7%-96.9%). Very high sensitivity and specificity were confirmed in the validation cohort (n=1465). Comparable findings were observed for the alternative 0/2-hour algorithm with ≤2 ng/L as the rule-out threshold. CONCLUSIONS: The alternative 0/1-hour and 0/2-hour algorithms using limit of quantification-based rule-out cutoffs of ≤2 ng/L with the hs-cTnI-VITROS assay demonstrated very high safety and efficacy in suspected myocardial infarction. REGISTRATION: URL: https://www.clinicaltrials.gov/; Identifier: NCT00470587.
2. Targeting Interleukin-8-Mediated Cellular Crosstalk Reverses Hypertrophic Cardiomyopathy and Cardiac Fibrosis in Noonan Syndrome.
Using human iPSC-based 2D/3D cardiac models, the study identifies cardiac fibroblast-derived IL-8 as a key paracrine driver of hypertrophy, fibrosis, and hypercontractility in Noonan syndrome. Pharmacologic blockade of IL-8–CXCR1 with reparixin reversed fibroblast and cardiomyocyte pathology, nominating a heart-autonomous, inflammation-independent target.
Impact: Reveals a previously unrecognized IL-8–mediated fibroblast–cardiomyocyte axis driving HCM/fibrosis and demonstrates pharmacologic reversibility, opening a translational path for rare, severe pediatric cardiomyopathy.
Clinical Implications: Although preclinical, targeting IL-8–CXCR1 (e.g., reparixin) may offer a precision therapy for NS-associated HCM; it also motivates cytokine signaling assessment in other hypertrophic/fibrotic cardiomyopathies.
Key Findings
- Cardiac fibroblast-specific IL-8 secretion drove fibrosis signatures, increased stiffness, cardiomyocyte hypertrophy, and hypercontractility in NS models.
- The IL-8–CXCR1 axis functioned as a heart-autonomous, inflammation-independent mechanism.
- Reparixin (IL-8–CXCR1 inhibitor) reversed pathological phenotypes in both fibroblasts and cardiomyocytes.
Methodological Strengths
- Use of complementary 2D and 3D human iPSC-based cardiac models to dissect paracrine mechanisms
- Pharmacologic rescue (reparixin) demonstrating causality and therapeutic reversibility
Limitations
- Preclinical in vitro models without in vivo validation or clinical trial data
- Specificity of effects to Noonan syndrome genotypes and broader cardiomyopathy contexts remains to be established
Future Directions: Validate in animal models and early-phase clinical trials; explore IL-8 axis in other hypertrophic/fibrotic cardiomyopathies and define biomarkers for patient selection.
BACKGROUND: Genetic variants in components or regulators of the RAS-MAPK signaling pathway are causative for severe and early-onset hypertrophic cardiomyopathy (HCM) in patients with Noonan syndrome (NS). Despite paracrine communication being considered to play a pivotal role in the etiology of cardiomyopathies, there is a paucity of knowledge about the underlying pathomechanism that leads to the development of hypertrophic cardiomyopathy and cardiac fibrosis in NS. METHODS: To dissect the impact of noncardiomyocytes in the development of NS, we employed two-dimensional and three-dimensional human induced pluripotent stem cell models of RESULTS: Our findings revealed that cytokine-mediated cellular crosstalk between cardiac fibroblasts and cardiomyocytes, predominantly activated in the disease state, serves as a primary driver of the disease. Cardiac fibroblast-specific IL-8 (interleukin-8) secretion induced fibrosis-related signatures, tissue stiffness, cardiomyocyte hypertrophy, and hypercontractility, identifying dysregulated IL-8 as a heart-autonomous signaling molecule independent of inflammation and immune cell involvement. Inhibition of IL-8-CXCR1 signaling by reparixin reversed the pathological effects in cardiac fibroblasts and cardiomyocytes. CONCLUSIONS: These data provide evidence that targeting aberrant IL-8-CXCR1 signaling may be an effective therapeutic option for patients with NS-associated hypertrophic cardiomyopathy.
3. PCSK9 inhibitor treatment and outcomes in patients with atherosclerotic cardiovascular disease but without prior ischaemic events: an observational study.
In 19,670 matched patients with ASCVD but no prior events, PCSK9 inhibitor initiation was associated with a 5-year absolute risk reduction of 7.8% (RRR 30.9%) in a composite of nonfatal MI, nonfatal ischemic stroke, or all-cause mortality, alongside ~54% LDL-C reduction. Reductions were consistent across MI, stroke, and mortality components.
Impact: Provides robust real-world evidence supporting PCSK9 inhibitors for high-risk ASCVD patients even before a first ischemic event, informing guideline updates and payer decisions.
Clinical Implications: For ASCVD patients with persistently elevated LDL-C despite standard therapy, PCSK9 inhibitors can substantially reduce event rates and mortality; implementation should consider cost-effectiveness and equitable access.
Key Findings
- 5-year composite event rates were 17.5% with PCSK9i vs 25.4% without (ARR 7.8%, RRR 30.9%; ITT).
- Relative risk reductions: MI 28.3%, ischemic stroke 26.4%, all-cause mortality 28.5%.
- On-treatment LDL-C fell from 117.8 to 54.7 mg/dL (−63.1 mg/dL; −53.6%).
Methodological Strengths
- Large propensity score–matched cohort with intention-to-treat analysis and parametric g-formula estimates
- Consistent effects across individual components and substantial lipid lowering
Limitations
- Observational design subject to residual confounding and selection biases
- Medication adherence, dosing, and lifestyle factors may be incompletely captured in claims data
Future Directions: Cost-effectiveness analyses in primary-prevention ASCVD subgroups; pragmatic trials optimizing initiation thresholds and adherence strategies.
BACKGROUND AND AIMS: Low-density lipoprotein cholesterol (LDL-C)-lowering therapies are proven effective in atherosclerotic cardiovascular disease (ASCVD), but real-world evidence for proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) monoclonal antibodies (mAb) remains limited. This study evaluated their impact in patients with ASCVD without prior ischaemic events. METHODS: Patients initiating PCSK9i mAb from January 2016 to December 2022 were identified in the Optum Research Database. A 1:2 propensity score-matched comparator cohort of PCSK9i non-initiators was developed. The primary endpoint was a composite of non-fatal myocardial infarction, non-fatal ischaemic stroke, or all-cause mortality. Key outcomes from the parametric G-formula were 5-year event rates, relative risk reduction (RRR) and absolute risk reduction (ARR), with intention-to-treat (ITT) analysis. Additional outcomes for PCSK9i mAb initiators included absolute and percent LDL-C reduction from baseline. RESULTS: Overall, 19 670 patients met selection criteria (6545 PCSK9i mAb initiators; 13 125 non-initiators). Baseline characteristics were well-balanced. Under ITT, estimated 5-year event rates were 17.5% [95% confidence interval (CI) 15.5%, 19.5%] with PCSK9i mAb vs 25.4% (95% CI 23.6%, 27.1%) without PCSK9i, yielding a RRR of 30.9% and ARR of 7.8%. Individual endpoints showed RRRs of 28.3% for myocardial infarction (P < .0001), 26.4% for ischaemic stroke (P = .02), and 28.5% for all-cause mortality (P < .0001). Among initiators, mean baseline and follow-up LDL-C were 117.8 and 54.7 mg/dL (on-treatment analysis), respectively, representing an absolute reduction of 63.1 mg/dL and percent reduction of 53.6%. CONCLUSIONS: In ASCVD patients without prior events in clinical practice, PCSK9i mAb treatment was associated with lower ischaemic event and mortality rates.